Gemcitabin

DRUG5 trials

Conditions

Advanced Stage or Metastatic Pancreatic Ductal AdenocarcinomaBiliary Tract Cancer (BTC)CYP3A InhibitorExtranodal NK/T-cell Lymphoma, Nasal TypeNon-Small Cell Lung CancerPancreatic AdenocarcinomaPancreatic CancerPancreatic Neoplasm

Phase 1

A Trial of Cobicistat and Gemcitabine and Nab-Paclitaxel in Patients with Advanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma

TerminatedNCT05494866

German Cancer Research CenterAdvanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma, CYP3A Inhibitor, Pancreatic Adenocarcinoma +2

Start: 2022-12-07End: 2024-03-15Updated: 2025-03-25

Phase 2

GPED Regimen for Relapsed/Refractory or Advanced ENKTCL

NCT04405375

Beijing Tongren HospitalExtranodal NK/T-cell Lymphoma, Nasal Type

Start: 2020-03-21End: 2023-04-30Target: 29Updated: 2020-05-28

Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma

Active, not recruitingNCT07480850

Cancer Institute and Hospital, Chinese Academy of Medical SciencesRefractory Diffuse Large B-Cell Lymphoma (DLBCL)

Start: 2026-01-01End: 2028-01-02Target: 40Updated: 2026-03-18

Phase 3

Phase III Study (Tarceva®) vs Chemotherapy to Treat Advanced Non-Small Cell Lung Cancer in Patients With Mutations in the TK Domain of EGFR

CompletedNCT00446225

Spanish Lung Cancer GroupNon-Small Cell Lung Cancer

Start: 2007-02-15End: 2012-12-31Updated: 2025-03-05

Unknown Phase

HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer

Not yet recruitingNCT07466238

Peking UniversityBiliary Tract Cancer (BTC)

Start: 2026-03-15End: 2029-03-15Target: 40Updated: 2026-03-27

Clinical and Translational Science2023-11-035 citations

AB036. Comparison of the effectiveness of gefitinib, erlotinib and afatinib in epidermal growth factor receptor mutated tumors of non-small cell lung cancer

Annals of Translational Medicine2016-11-01

Association of<i>EGFR</i>L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial

JAMA Oncology2015-02-26234 citations

ROR1 as a novel therapeutic target for EGFR-mutant non-small-cell lung cancer patients with the EGFR T790M mutation.

2014-06-0126 citations

The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial.

2014-02-03193 citations

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

2012-01-264247 citations